WS #16552
Eli Lilly surged to all-time highs, driven by strong demand for its GLP-1 drugs Mounjaro and Zepbound, which saw significant sales increases. The company raised its 2026 guidance, demonstrating the enduring strength of the weight-loss drug market. This rally provides a bright spot in an otherwise challenging tech environment, attracting capital into the healthcare sector as a defensive growth play.
Lilly and Pharma Rally
Eli Lilly surged to all-time highs, driven by strong demand for its GLP-1 drugs Mounjaro and Zepbound, which saw significant sales increases. The company raised its 2026 guidance, demonstrating the enduring strength of the weight-loss drug market. This rally provides a bright spot in an otherwise challenging tech environment, attracting capital into the healthcare sector as a defensive growth play.